Short Interest in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Drops By 20.7%

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) was the target of a large decrease in short interest in the month of May. As of May 31st, there was short interest totalling 542,900 shares, a decrease of 20.7% from the May 15th total of 684,400 shares. Based on an average daily trading volume, of 149,300 shares, the days-to-cover ratio is currently 3.6 days. Currently, 3.1% of the company’s stock are short sold.

Analyst Upgrades and Downgrades

A number of analysts have commented on LXEO shares. Baird R W raised Lexeo Therapeutics to a “strong-buy” rating in a report on Thursday. HC Wainwright started coverage on Lexeo Therapeutics in a report on Thursday, June 6th. They set a “buy” rating and a $22.00 price objective for the company. Finally, Robert W. Baird started coverage on Lexeo Therapeutics in a report on Thursday. They set an “outperform” rating and a $28.00 price objective for the company. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $22.00.

Hedge Funds Weigh In On Lexeo Therapeutics

Several institutional investors have recently modified their holdings of the business. RA Capital Management L.P. bought a new position in Lexeo Therapeutics during the first quarter valued at $10,364,000. Artal Group S.A. grew its holdings in Lexeo Therapeutics by 32.9% during the first quarter. Artal Group S.A. now owns 801,716 shares of the company’s stock valued at $12,571,000 after purchasing an additional 198,281 shares during the period. Janus Henderson Group PLC grew its holdings in Lexeo Therapeutics by 9.0% during the first quarter. Janus Henderson Group PLC now owns 2,540,785 shares of the company’s stock valued at $39,802,000 after purchasing an additional 210,047 shares during the period. American International Group Inc. bought a new position in Lexeo Therapeutics during the first quarter valued at $79,000. Finally, Vanguard Group Inc. grew its holdings in Lexeo Therapeutics by 15.8% during the first quarter. Vanguard Group Inc. now owns 481,755 shares of the company’s stock valued at $7,554,000 after purchasing an additional 65,573 shares during the period. 60.67% of the stock is owned by institutional investors.

Lexeo Therapeutics Stock Performance

Shares of LXEO stock traded down $1.38 during trading on Friday, hitting $17.38. The company’s stock had a trading volume of 143,261 shares, compared to its average volume of 174,495. The company has a market cap of $572.50 million and a PE ratio of -0.78. The company has a current ratio of 9.16, a quick ratio of 9.16 and a debt-to-equity ratio of 0.01. The business has a fifty day moving average of $14.33 and a 200-day moving average of $14.82. Lexeo Therapeutics has a 52 week low of $9.00 and a 52 week high of $22.33.

Lexeo Therapeutics (NASDAQ:LXEO) last released its earnings results on Thursday, May 9th. The company reported ($0.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.01). As a group, research analysts anticipate that Lexeo Therapeutics will post -2.65 earnings per share for the current year.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.